In a report issued on January 28, Mani Foroohar from Leerink Partners maintained a Hold rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $1.00. The company’s shares closed last Monday at $0.26, close to its 52-week low of $0.21.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -17.9% and a 37.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abeona Therapeutics with a $4.00 average price target.
Abeona Therapeutics’ market cap is currently $38.5M and has a P/E ratio of -0.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Read More on ABEO:
- Leerink Partners Maintains Their Hold Rating on Wave Life Sciences (WVE)
- Leerink Partners Sticks to Its Hold Rating for Bluebird Bio (BLUE)
- Leerink Partners Maintains Their Buy Rating on Decibel Therapeutics (DBTX)
- Leerink Partners Maintains Their Buy Rating on Amryt Pharma (AMYT)
- Leerink Partners Thinks Talaris Therapeutics’ Stock is Going to Recover